22184-00-5

Basic information

• Product Name: 2-(methyl-5-(4-methylphenyl))-2-pentanol
• Synonyms: 2-(methyl-5-(4-methylphenyl))-2-pentanol
• CAS NO: 22184-00-5
• Molecular Weight: 192.301
• Mol File: 22184-00-5.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 2-(methyl-5-(4-methylphenyl))-2-pentanol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(methyl-5-(4-methylphenyl))-2-pentanol(22184-00-5)
• EPA Substance Registry System: 2-(methyl-5-(4-methylphenyl))-2-pentanol(22184-00-5)

Safety Data

• Hazardous Substances Data: 22184-00-5(Hazardous Substances Data)

Upstream product

• 24306-23-8 methyl 4-(4-methylphenyl)butanoate 
• 4521-22-6 4-(4-methylphenyl)butyric acid 
• 108-88-3 toluene 
• 4619-20-9 3-(4-methylbenzoyl)propionic acid 
• 917-64-6 methyl magnesium iodide 

Downstream Products

• 98453-65-7 C₂₀H₂₂N₂O₂S 
• 22824-34-6 1,2,3,4-tetrahydro-1,1,7-trimethyl-naphthalene 

Relevant articles and documents

Enantioselective C-H Amination Catalyzed by Nickel Iminyl Complexes Supported by Anionic Bisoxazoline (BOX) Ligands

The trityl-substituted bisoxazoline (TrHBOX) was prepared as a chiral analogue to a previously reported nickel dipyrrin system capable of ring-closing amination catalysis. Ligand metalation with divalent NiI2(py)4 followed by potassium graphite reduction afforded the monovalent (TrHBOX)Ni(py) (4). Slow addition of 1.4 equiv of a benzene solution of 1-adamantylazide to 4 generated the tetrazido (TrHBOX)Ni(κ2-N4Ad2) (5) and terminal iminyl adduct (TrHBOX)Ni(NAd) (6). Investigation of 6 via single-crystal X-ray crystallography, NMR and EPR spectroscopies, and computations revealed a Ni(II)-iminyl radical formulation, similar to its dipyrrinato congener. Complex 4 exhibits enantioselective intramolecular C-H bond amination to afford N-heterocyclic products from 4-aryl-2-methyl-2-azidopentanes. Catalytic C-H amination occurs under mild conditions (5 mol % catalyst, 60 °C) and provides pyrrolidine products in decent yield (29%-87%) with moderate ee (up to 73%). Substrates with a 3,5-dialkyl substitution on the 4-aryl position maximized the observed enantioselectivity. Kinetic studies to probe the reaction mechanism were conducted using 1H and 19F NMR spectroscopies. A small, intermolecular kinetic isotope effect (1.35 ± 0.03) suggests an H-atom abstraction step with an asymmetric transition state while the reaction rate is measured to be first order in catalyst and zeroth order in substrate concentrations. Enantiospecific deuterium labeling studies show that the enantioselectivity is dictated by both the H-atom abstraction and radical recombination steps due to the comparable rate between radical rotation and C-N bond formation. Furthermore, the competing elements of the two-step reaction where H-removal from the pro-R configuration is preferred while the preferential radical capture occurs with the Si face of the carboradical likely lead to the diminished ee observed, as corroborated by theoretical calculations. Based on these enantio-determining steps, catalytic enantioselective synthesis of 2,5-bis-tertiary pyrrolidines is demonstrated with good yield (50-78%) and moderate ee (up to 79%).

BEXAROTENE DERIVATIVES AND THEIR USE IN TREATING CANCER

This disclosure relates to compositions and methods for treating cancer. Specifically, this disclosure relates to bexarotene derivatives, methods for treating cancer, autoimmune disorders, and/or skin dermatitis, and/or methods for increasing peripheral blood counts and/or improving immune system function.

Retinoic acid receptor antagonists as promoters of angiogenesis

Methods and compositions for treating various disorders by administering a therapeutically effective amount of a retinoic acid receptor antagonist alone or in combination or in conjunction with other therapeutic agents to promote angiogenesis are provided